source
- French regulator fines Novo Nordisk and Eli Lilly for misleading weight loss adsFrench medicines regulator ANSM imposed fines on Novo Nordisk and Eli Lilly for advertising practices linked to their weight loss drugs. Novo Nordisk was fined about $2 million for ads promoting W…
- Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancerOn May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…